Fornits

Fornits Home for Wayward Web Fora
An open discussion about the troubled parent industry

How this place is still running is beyond me, It's appalling. Lumping victims of rape and abuse, kids suffering from depression and kids dealing with drug addictions together under one "treatment" isn't the way to "achieve lasting change". Last time I checked, using restraints like they do isn't either. This place needs to go.

HELL FUCKIN YEA!!!!!

Quote from: ""TheWho""

The body net seems to be designed to keep the patient cooler (for use in warmer climates maybe)
...

Like they give a shit about the kid's comfort...

 :rofl:  :rofl:  :rofl:

Quote from: ""TheWho""

Quote from: ""ZenAgent""

Quote from: ""SettleForNothingLess""

Here is an example of one of my restraints:
Mechanical restraint started at 1:55 PM. Mechanical restraint DCed at 9:55 PM. thats 7 hours of being tied down. 5 Mgs of Haldol, 50 Mgs of Benadryl, and 15 Mgs of Zyprexa Zydis administered at 5:10 PM.
Restrain using body net.

Zyprexa
Indications & Dosage

Efficacy in schizophrenia was demonstrated in a dose range of 10 to 15 mg/day in clinical trials. However, doses above 10 mg/day were not demonstrated to be more efficacious than the 10 mg/day dose. An increase to a dose greater than the target dose of 10 mg/day (i.e., to a dose of 15 mg/day or greater) is recommended only after clinical assessment. The safety of doses above 20 mg/day has not been evaluated in clinical trials

Children require smaller dosages of haloperidol than do adults. The recommended initial dosage of haloperidol for controlling psychotic symptoms in children is 0.5–2.0 mg two or three times each day. The recommended dosage for controlling symptoms of Tourette's syndrome and other non-psychotic disorders is between 0.075 and 0.05 mg per kilogram of body weight per day. The total dosage is usually divided into two or three administrations per day. The goal of therapy is to use the smallest amount of haloperidol that will control symptoms. Children under age three should not take this drug.

Is PV trying to cover-up their ignorance of therapy with an abundance of pharmacy?  That's sickening, and it seems incredibly ignorant to administer all that to you at once, and criminal to give you those dosages.

Zen, we really cannot say, by just looking at a log, if the amounts were appropriate or not.

Zeprexa is manufactured in tablet doses of:

2.5, 5, 7.5, 10, 15, 20 mg.

Treatment of bipolar disorder usually is initiated with oral doses of 10-15 mg once daily. The dose may be increased by 5 mg daily at 24 hour intervals. Doses greater than 20 mg daily have not been evaluated. In clinical trials, doses of 5-20 mg daily were effective.


You need to be careful how you distinguish between treatment and chemical restraint.  If a person is being administered a drug as part of their treatment then it is not considered a restraint.  If a drug is being administered to control a person’s behavior then it could be considered dosing for restraint.  So it is the process of prescribing rather than the agent prescribed that distinguishes treatment from restraint.



...

It was not the argument about Zyprexa... it was why administer HALDOL, BENADRYL, and ZYPREXA   all at the same time??? whats the point of a cocktail like that?

And all of those were recieved while tied down to a bed, whats the point? and no they were not a part of my medication regiment....

i am 20 now..21 in may.... i was in 4 programs... bleh... SUWS, ASR, PV, and Meridell

Quote from: ""Stay on subject""

Now the tread is beginning to be about relationship between who and CCM. That is exactly as interesting as reading about Amber and Peter, when they were fooled into Foreland Hamlet.

Could we discuss reality instead?

How can we get into the parent group on google? They must have a idea about what a body net is?

I know that the parents here on this forum did not place their kid in PV, but what did they think the body net and the jacket meant? They use so nice words, but do they fool anyone?

Zen: What did you think that they meant with the jacket and net before you actually saw it?

Settle: Did you ever discuss these items with your parents? Did they know what they actually consented to?

We didn't get a copy of the handbook when our girl was placed in PV, we had to ask for it.  By then, we had already learned the place was hell, the handbook only made it worse.  We had already read about the "burrito", the straitjacket.  It's a straitjacket to me, maybe that's not acceptable anymore.

And my response to the question asked is unfortunatly my dad wont talk to me about it.

I seeded thru all of my medication regimen last night. This is just for my abilify.
9/3 thru 9/8   5 Mgs at 5P
9/9 thru 9/12  10mgs at 9PM
9/13 thru 9/15   15 mgs at 9PM
9/16 thru 9/29    20mgs at 9 PM
9/30 thru 10/7    20mgs at 8AM and 20Mgs at 9PM (40 Mgs)
10/8 thru 10/19   40 mgs at 9PM
10/20 thru 10/27  20Mgs at 1PM and 40Mgs at 9PM   (60Mgs)
10/27 thru 10/30    40Mgs at 1PM and 40 Mgs at 9PM (80 Mgs)
10/31 thru 11/2      40 Mgs at 1PM and 60 Mgs at 9PM  (100Mgs)
11/2 thru 11/18     60 Mgs at 1PM and 60 Mgs at 9PM  (120 Mgs)


then when they were getting ready for discharge, it starts going down  drastically.


Aripiprazole (Abilify) for schizophrenia

(ari-pip-rah-zol)
Summary
PBS listing:  Authority required
Schizophrenia
Reason for listing:  Listing was recommended on a cost-minimisation basis against olanzapine, suggesting similar benefits at similar or reduced cost to the PBS.
Place in therapy:  There is presently no evidence to suggest that aripiprazole is more effective than existing antipsychotics in the treatment of schizophrenia but it offers prescribers another treatment option for this illness. Based on its tolerability profile, it can be considered another atypical antipsychotic.
Safety issues:  The risk of extrapyramidal side-effects and hyperprolactinaemia appears low with aripiprazole at recommended doses. In clinical trials, weight gain was less than with olanzapine. Diabetes, hyperlipidaemia, tardive dyskinesia and QT prolongation have not been identified as problems in clinical trials but more post-marketing experience is needed to determine its long-term safety profile. The dose of aripiprazole may need to be adjusted if co-administered with carbamazepine, or inhibitors of enzymes CYP3A4 (e.g. ketoconazole, erythromycin) or CYP2D6 (e.g. fluoxetine, paroxetine).
Dosing issues:  The recommended starting and maintenance dose is 15 mg once daily. The maximum approved dose is 30 mg daily, but there is no evidence that doses over 15 mg are more effective.
PBS listing
Authority required

Schizophrenia.

TOP ^
Reason for PBS listing
Listing was recommended on a cost-minimisation basis against olanzapine1, suggesting similar benefits at similar or reduced cost to the PBS.

TOP ^
Place in therapy
Aripiprazole is a new antipsychotic agent. There is presently no evidence to suggest that it is more effective than existing antipsychotics in the treatment of schizophrenia but it offers prescribers another treatment option for this illness. Its efficacy in treatment-resistant schizophrenia is not established; for these patients clozapine is generally considered the drug of choice.2-4

Antipsychotic drugs are generally classified into two groups: the older or 'conventional' agents (e.g. haloperidol, chlorpromazine) and the newer or 'atypical' agents (amisulpride, clozapine, olanzapine, quetiapine and risperidone).

Conventional antipsychotics are effective at reducing positive symptoms of schizophrenia, such as hallucinations and delusions, but are commonly associated with distressing adverse effects such as extrapyramidal side-effects† and hyperprolactinaemia.2-4

Atypical antipsychotics are at least as efficacious at treating positive symptoms as the conventional agents and may be more effective in managing negative symptoms2-4 (see Table 1). Atypical antipsychotics are less likely to cause extrapyramidal effects and hyperprolactinaemia, although both risperidone and amisulpride may induce these effects at higher doses.2,4

While aripiprazole has been described as a 'novel antipsychotic agent'5 (a 'dopamine system stabiliser'6), the clinical relevance of this mechanism of action is as yet unknown. Based on its tolerability profile it can be considered another atypical antipsychotic.7

Atypical antipsychotics are often preferred to conventional agents in the treatment of schizophrenia2,3 but the Therapeutic Guidelines: Psychotropic does not distinguish between the older and newer agents and argues that choice of antipsychotic drug and dose should be individualised to suit the patient.4

†includes Parkinsonism, dystonia, akathisia (restlessness) and tardive dyskinesia.

Table 1: Symptoms of schizophrenia2,4
Positive symptoms


hallucinations
delusions
 Negative symptoms


blunted affect
loss of sense of pleasure (anhedonia)
poor self-care
impoverished speech
apathy/lack of motivation
attentional impairment*
social withdrawal
 Cognitive symptoms


impaired planning and problem-solving (executive functioning)
impaired memory
impaired language processing
 

*also considered a cognitive symptom.

Aripiprazole efficacy studies

Few published studies compare aripiprazole directly with other antipsychotics in the treatment of schizophrenia and it is difficult to draw conclusions about its relative efficacy, particularly compared with other atypical agents. Aripiprazole has been compared with olanzapine in clinical trials8 but, as yet, efficacy data have not been published.

A recent meta-analysis compared the efficacy of atypical and conventional antipsychotics.9 Of the atypicals, only clozapine, amisulpride, risperidone and olanzapine were found to be more effective than the older drugs, but the analysis of aripiprazole was based on limited data.

Aripiprazole 10–30 mg was significantly better than placebo‡ in three short-term (4–6 week) double-blind trials in schizophrenia and schizo-affective disorder, although two earlier dose-ranging studies failed to demonstrate efficacy.10 Some studies included an active control (either haloperidol or risperidone)10-12 but were not powered to allow a direct comparison with aripiprazole.5

Two long-term, double-blind, maintenance studies have been conducted.13,14 A 6-month comparison with placebo found that patients taking placebo relapsed significantly sooner and more frequently than those taking aripiprazole 15 mg.13 In a 52-week study of more than 1200 patients with acute relapse of chronic schizophrenia, aripiprazole was not superior to haloperidol in the primary efficacy endpoint, time-to-failure to maintain response, but was better tolerated.14

Published studies exclude patients with treatment-refractory schizophrenia, a history of suicide attempts or ideation, and/or past or current substance abuse; results therefore cannot be generalised to these patient groups. Only one study enrolled patients aged over 65 years. Patients aged less than 18 years were excluded and the safety and effectiveness of aripiprazole in this age group is not established.5

‡Efficacy was assessed using standardised instruments, including the Positive and Negative Syndrome Scale (PANSS), the Brief Psychiatric Rating Scale (BPRS), and the Clinical Global Impression (CGI).

If switching patients to aripiprazole

An 8-week outpatient study found that any of the following methods could be used if switching patients from other antipsychotics†† to aripiprazole5,15:


immediate initiation of aripiprazole and immediate cessation of current antipsychotic;
immediate initiation of aripiprazole and a 2-week taper of current antipsychotic;
2-week up-titration of aripiprazole with simultaneous taper of current antipsychotic.


Prescribing guidelines generally advocate a simultaneous taper method to minimise antipsychotic withdrawal effects.2,4

††Most patients in the study were taking either olanzapine or risperidone.

TOP ^

 
Safety issues
The risk of extrapyramidal side-effects and hyperprolactinaemia appears low with aripiprazole at recommended doses.10 In clinical trials weight gain was less than with olanzapine.5,10 Diabetes, hyperlipidaemia, tardive dyskinesia and QT prolongation have not been identified as problems in clinical trials10 but more post-marketing experience is needed to determine its long-term safety profile. The dose of aripiprazole may need to be adjusted if co-administered with potent CYP2D6 or CYP3A4 inhibitors or inducers (see Drug interactions).5

Contra-indications and precautions

The general contra-indications, warnings and precautions for aripiprazole are similar to those of other atypical antipsychotics; refer to the Abilify product information.5

Aripiprazole demonstrated developmental toxicity in animal studies and if possible should be avoided in pregnancy.5

The UK Committee of Safety of Medicines (CSM) has recently warned that atypical antipsychotics (although not specifically aripiprazole) may increase the risk of stroke in elderly patients with dementia.16

Adverse drug reactions

Weight gain can occur with most atypical agents but clozapine and olanzapine tend to cause the greatest short-term gains in weight.17 Long-term comparisons found aripiprazole was more likely than haloperidol (20% vs. 13%) to be associated with significant weight gain‡‡, but less likely than olanzapine (13% vs. 33%).5,10

A recent consensus statement on antipsychotic drugs, obesity and diabetes concluded that aripiprazole was associated with little or no significant weight gain, diabetes or dyslipidaemia, with the caveat that it had not been used as extensively as other atypical agents.17 Nevertheless, the Food and Drug Administration (FDA) has requested that all atypical antipsychotics include a diabetes warning statement in US product information.18

In short-term trials the incidence of extrapyramidal side-effects was similar to placebo, although akathisia was slightly more common with aripiprazole.5,10 In long-term comparisons the incidence of extrapyramidal effects was comparable to that with olanzapine but significantly less than with haloperidol.5,10

QT prolongation can occur with some antipsychotic drugs and predispose patients to the potentially fatal arrhythmia, torsade de pointes.3,4 QTc prolongation has not been reported with aripiprazole at recommended doses but may be a potential problem in overdose.10

Increased prolactin levels have not been reported with aripiprazole in clinical trials.10

Orthostatic hypotension may occur.5

‡‡≥ 7% increase from baseline

Drug interactions

If potent inhibitors of enzymes CYP2D6 (e.g. fluoxetine, paroxetine) and CYP3A4 (e.g. ketoconazole, erythromycin) are co-administered the dose of aripiprazole may need to be reduced.5

The potent CYP3A4 inducer, carbamazepine, increases the clearance of aripiprazole; if co-administered the dose of aripiprazole should be doubled.5

TOP ^
 
Dosing issues
The recommended starting and maintenance dose is 15 mg once daily.5 The maximum approved dose is 30 mg daily5 but there is no evidence that doses over 15 mg are more effective.10

For further information on dosing, drug interactions and adverse effects consult the Australian Medicines Handbook or the Abilify product information.

TOP ^  
Information for patients
As with any antipsychotic therapy, many patients taking aripiprazole may relapse or discontinue therapy in the longer-term.13,14 Poor compliance and substance misuse are common triggers for relapse and patients and carers should be counselled about the dangers of these.2-4

For more detailed information, suggest or provide the Abilify Consumer Medicine Information (CMI).

TOP ^
 
References
Department of Health and Ageing. December 2003 PBAC outcomes – positive recommendations.
http://www.health.gov.au/pbs/general/li ... IPIPRAZOLE. (Accessed 11 February 2004).
Lambert TJR, Castle DJ. Med J Aust 2003;178:S57–S61.
Freedman R. N Engl J Med 2003;349:1738–49.
Therapeutic Guidelines: Psychotropic. Version 5, 2003.
Abilify Product Information. Bristol Myers Squibb Pty Ltd. 14 July 2003.
Stahl SM. J Clin Psychiatry 2001;62:11:841–2.
European Agency for the Evaluation of Medicinal Products. Pre-authorisation Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products Summary of Opinion for Abilify. London, 26 February 2004. http://www.emea.eu.int/pdfs/human/opinion/563403en.pdf (Accessed 2 February 2004.)
The Cochrane Central Register of Controlled Trials. The Cochrane Library. Issue 1, 2004. (Accessed 26 February 2004.)
Davis JM, Chen N. Arch Gen Psychiatry 2003;60:553–564.
US Food & Drug Administration Center for Drug Evaluation and Research, New and Generic Drug Approvals: Abilify (aripiprazole). 3 July 2003. http://www.fda.gov/cder/approval/index.htm (Accessed December 2003.)
Potkin S, et al. Arch Gen Psychiatry 2003;60:681–90.
Kane JM, et al. J Clin Psychiatry 2002;63:763–71.
Pigott TA, et al. J Clin Psychiatry 2003;64:1048–56.
Kasper S, et al. Int J Neuropsychopharmacol 2003;6:325–37.
Casey DE, et al. Psychopharmacol 2003;166:391–9.
Committee of Safety of Medicines. Atypical antipsychotic drugs and stroke. 9 March 2004. http://medicines.mhra.gov.uk/ourwork/mo ... e_9304.htm (Accessed 10 March 2004.)
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Diabetes Care 2004;27:596–601.
2004 Safety Alert: Zyprexa (olanzapine). US FDA Medwatch. http

::puke::

Thanks dude you just fucked up my day with that video, kill PV!  :flame:

hanzomon4

hell ya may they burn in hell.... god 98... holy shiiiiiat

Well I have been counting my restraints, so far Im up to 98 in less than 6 months. BASTARDS.